MedTrace Logo

ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.

NCT00440479 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2015-04-16

No results posted yet for this study

Summary

The primary aim of this observational study is to collect safety and effectiveness data for bortezomib used at first relapse in a group of multiple myeloma patients who received specific and well defined first line treatments within previous clinical studies.

Conditions

Interventions

DRUG

Bortezomib

dose as determined (observational study) by treating physician

Sponsors & Collaborators

  • Janssen-Cilag B.V.

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag B.V. Clinical Trial · Janssen-Cilag B.V.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00440479 on ClinicalTrials.gov